Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8311 to 8325 of 9128 results

  1. Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

    Discontinued Reference number: GID-TAG425

    Technology appraisal guidance
    Discontinued

  2. Digital technologies for the early detection and initial diagnosis of adult hearing loss (provisional title)

    Discontinued Reference number: GID-HTG10172

    HealthTech guidance
    Discontinued

  3. Vosoritide for treating achondroplasia in people 4 months and over [ID6488]

    In development Reference number: GID-TA11528 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Dupilumab for treating chronic spontaneous urticaria inadequately controlled by H1 antihistamines in children 2 to 11 years [GID-TA12472]

    In development Reference number: GID-TA12472 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Satralizumab for treating relapsing myelin oligodendrocyte glycoprotein antibody associated disease [GID-TA12471]

    In development Reference number: GID-TA12471 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Osteoarthritis - naproxcinod [ID417]

    Discontinued Reference number: GID-TAG426

    Technology appraisal guidance
    Discontinued

  7. Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions [ID463]

    Discontinued Reference number: GID-TAG427

    Technology appraisal guidance
    Discontinued

  8. Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415]

    Discontinued Reference number: GID-TAG431

    Technology appraisal guidance
    Discontinued

  9. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued Reference number: GID-TAG432

    Technology appraisal guidance
    Discontinued

  10. T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

    Discontinued Reference number: GID-TAG433

    Technology appraisal guidance
    Discontinued

  11. Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

    Discontinued Reference number: GID-TAG435

    Technology appraisal guidance
    Discontinued

  12. Hypercholesterolemia - mipomersen [ID524]

    Discontinued Reference number: GID-TAG437

    Technology appraisal guidance
    Discontinued

  13. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued Reference number: GID-TAG440

    Technology appraisal guidance
    Discontinued

  14. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued Reference number: GID-TAG454

    Technology appraisal guidance
    Discontinued

  15. Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

    Discontinued Reference number: GID-TAG456

    Technology appraisal guidance
    Discontinued